Treatment of chronic obstructive pulmonary disease - Traditional bronchodilatation and targeted anti-inflammatory therapy;Leczenie przewlekłej obturacyjnej choroby płuc - Bronchodylatacja i przeciwzapalna farmakoterapia celowana

Pneumonologia i Alergologia Polska

Volumn 79, Issue 1, 2011, Pages 32-38

  Mróz, Robert M ^a   Skopiński, Tomasz ^a   Hołownia, Adam ^b   Chyczewska, Elzbieta ^a   Braszko, Jan J ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Zaklad Genetyki Klinicznej   (Poland)

Author keywords

Anticholinergic agents; COPD; Corticosteroids

Indexed keywords

ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; HUMAN; SMOKING;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 78651419515     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kozielski J., Chazan R., Gorecka D. i wsp. Zalecenia Polskiego Towarzystwa Ftyzjopneumonologicznego rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc. Pneumonol. Alergol. Pol. 2002;70:2-42.
2. Zalecenia Polskiego Towarzystwa Ftyzjopneumonologicznego rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc. Pneumonol. Alergol. Pol. 2004;72:1-28.
3. Gorecka D., Zielinski J. Wczesne rozpoznawanie i profilaktyka POChP w Polsce; stan obecny i perspektywy. Pneumonol. Alergol. Pol. 2005;73:112-115.
4. Rabe K. F., Hurd S., Anzueto A. i wsp. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care. Med. 2007;176:532-555.
5. Barnes P. J. Advances in COPD. Intern. Med. J. Thai. 2006;22:68-73.
6. Barnes P. J. Mediators of chronic obstructive pulmonary disease. Pharm. Rev. 2004;56:515-548.
7. Adcock I. M., Lane S. J. Mechanisms of steroid action and resistance in inflammation. J. Endocrinology 2003;178:347-355.
8. Perng D. W., Huang H. Y., Chen H. M., Lee Y. C., Perng R. P. Characteristic of airway inflammation and bronchodilator reversibility in COPD. Chest 2004;126:375-381.
9. Belmonte K. E. Cholinergic pathways in the lung and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005;2:297-304.
10. 4 production and neutrophilic inflammation in COPD patients. Allergy 2005;60:1361-1369.
11. 3 antagonists. Med. Res. Rev. 2009;29:1-36.
12. 3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur. Respir. J. 2009;34:1-28.
13. Koumis T., Samuel S. Tiotropium Bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin. Therapeutics 2005;2:377-392.
14. Buhling F., Lieder N., Kuhlmann U. C., Waldburg N., Welte T. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Resp. Med. 2007;101:2386-2394.
15. Pahl A., Bauhofer A., Petzold U. i wsp. Synergistic effect of the anti-cholinergic R, R-glycopyrrolate with anti-inflammatory drug. Bioch. Pharm. 2006;72:1690-1696.
16. Iesato K., Tatsumi K., Saito K. i wsp. Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells. Respiration 2008;76:434-441.
17. Allfrey V. G., Faulkner R., Mirsky A. E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. 1964;51:786-794.
18. Ito K., Ito M., Elliott W. M. i wsp. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005;352:1967-1976. (Pubitemid 40638367)
19. Barnes P. J., Adcock I. M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005;25:552-563. (Pubitemid 40331188)
20. Bhavsar P. K., Ahmad T., Adcock I. M. The role of histone deacetylases in asthma and allergic diseases. J. Allergy Clin. Immunol. 2008;121:580-584.
21. Adcock I. M., Barnes P. J. Molecular mechanisms of corticosteroid resistance. Chest 2008:134: 394-401.
22. Bhavsar P. K., Khorasani N. J. M. Improvement in corticosteroid sensitivity in PBMCs from patients with COPD by p38 MAPK inhibition. Am. J. Respir. Crit. Care Med. 2009;179: A6187.
23. Marwick J. A., Caramori G., Stevenson C. S. i wsp. Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am. J. Respir. Crit. Care Med. 2009;179:542-548.
24. Ford P. A., Durham A. L., Russell R. E., Gordon F., Adcock I. M., Barnes P. J. Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010;137:1338-1344.
25. Alexeeff S. E., Litonjua A. A., Sparrow D., Vokonas P. S., Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am. J. Respir. Crit. Care Med. 2007;176:742-747.
26. Hothersall E., McSharry C., Thomson N. C. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-734.
27. Soyseth V., Brekke P. H., Smith P., Omland T. Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 2007;29:279-283.
28. Keddissi J., Younis W. G., Chbeir E., Daher N., Dernaika T., Kinasewitz G. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-1771.
29. Blamoun A. I., Batty G. N., DeBari V. A., Rashid A. O., Sheikh M., Khan M. A. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008;62:1373-1378.
30. Lee T. M., Lin M. S., Chang N. C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am. J. Cardiol. 2008;101:530-535.
31. Liao J. K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005;45:89-118.
32. Schonbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109: II18-II26.
33. Wierzbicki A. S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 2003;99:95-112.
34. Wagner A. H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 2000;20:61-69.
35. Martinez-Gonzalez J., Escudero I., Badimon L. Simvastatin potenciates PGI2 release induced by HDL in human VSMC: effect on COX-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis 2004;174:305-313.
36. Dobler C. C., Wong K. K., Marks G. B. Associations between statins and COPD: a systematic review. BMC. Pulm. Med. 2009;9:32.
37. Borghi C., Prandin M. G., Costa F. V., Bacchelli S., Esposti D. D., Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 2000;35:549-555.
38. Hernandez-Perera O., Pérez-Sala D., Navarro-Antolín J. i wsp. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 1998;101:2711-2719.
39. Janda S., Park K., FitzGerald J. M., Etminan M., Swiston J. Statins in COPD: a systematic review. Chest 2009;136:734-743.
40. Mroz R. M., Holownia A., Chyczewska E. i wsp. Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease. J. Physiol. Pharmacol. 2007;58:437-444.
41. Holownia A., Mroz R. M., Kolodziejczyk A., Chyczewska E., Braszko J. J. Increased FKBP51in induced sputum cells of chronic obstructive pulmonary disease patients after therapy. Eur. J. Med. Res. 2009;14:108-111.
42. Moore A. R., Willoughby D. A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 1995;101:387-389.
43. Martina S. D., Ismail M. S., Vesta K. S. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann. Pharmacother. 2006;40:1822-1828.
44. Rabe K. F., Bateman E. D., O'Donnell D., Witte S., Bredenbroker D., Bethke T. D. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-571.
45. Calverley P. M. A., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L. M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007;176:154-161.
46. Calverley P. M. A., Rabe K. F., Goehring U-M., Kristiansen S., Fabbri L. M., Martinez F. J., for the M2-124 and M2-125 study groups. Roflumilast in symptome chronic obstructive pulmonary disease: two randomised clinical trals. Lancet 2009;374:685-694.
47. Davis T. G., Peterson J. J., Kou J. P. i wsp. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl) methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b] pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity. J. Pharmacol. Exp. Ther. 2009;330:922-931.